Drug Trial Radar · NCT03015909
Evaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj.
Last checked: Nov 20, 2026Latest source record: Jan 3, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
116
Actual
Start
Aug 11, 2016
Primary completion
Dec 21, 2017
Study completion Dec 21, 2017
Sponsor
- Lead sponsor
- LG Life SciencesIndustry
- Sponsor type
- Industry
- First posted
- Jan 10, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 4 years, up to 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the ease of use, preference, and safety after 8 weeks subcutaneous administration of EutropinPen Inj. in patients pretreated with recombinant human growth hormone by reusable device.
Conditions
- Short Stature, Idiopathic
- Infant, Small for Gestational Age
- Growth Hormone Deficiency
- Chronic Renal Failure
- Turner Syndrome
Interventions
SomatropinDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ease of use for EutropinPen Inj. against previous reusable device assessed by a questionnaire.Time frame: Day 57
- Preference for EutropinPen Inj. against previous reusable device assessed by a questionnaire.Time frame: Day 57
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ajou university hospital
Suwon, Gyeonggi-do, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.